Table 1.
Patient clinical and demographic data. Age, age at diagnosis. MGMT (O-6-methylguanine-DNA methyltransferase), percentage of MGMT promoter methylation. Region, tumor location and surgical resection area. Therapy, Radiotherapy (RT) and chemotherapy with temozolomide (TMZ). RFS, recurrence-free survival. OS, overall survival.
| Tumor | Sex | Age | MGMT | Region | Therapy | RFS | OS |
|---|---|---|---|---|---|---|---|
| GB01 | F | 55 | 8% | Left peritrigonal area | TMZ concurrent with RT followed by adjuvant TMZ | 13 months | 20 months |
| GB02 | F | 74 | 56% | Right parietal lobe | RT | nd | nd (>6 months) |
| GB03 | F | 58 | <7% | Right frontal-temporal-parietal area | TMZ concurrent with RT followed by adjuvant TMZ | 16 months | 20 months |